For patients with HER2+ early breast cancer cT1c (i.e., >1 to ≤2 cm) without evidence of nodal disease (cN0), the standard of care is surgery followed by adjuvant treatment (strong recommendation). This evidence concerns the gene ERBB2 and breast carcinoma.